|   |
|---|
|   |  |
| x | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |

|   |
|---|
|   |  |
| o | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |

|                                                                   |
|-------------------------------------------------------------------|
|                                                                   |  |
| DELAWARE                                                          | 22-2343568 |
| (State or other jurisdiction of                                   | (I.R.S. Employer |
| incorporation or organization)                                    | Identification No.) |
|                                                              |   |
| 106 ALLEN ROAD, FOURTH FLOOR                    BASKING RIDGE, NJ | 07920 |
| (Address of principal executive offices)                          | (zip code) |

|                                                                                                                     |
|---------------------------------------------------------------------------------------------------------------------|
|                                                                                                                     |  |
| Large accelerated filer     o                                                              | Accelerated filer     x |
| Non-accelerated filer   o     (Do not check if a smaller reporting company) | Smaller reporting company     o |

----

----

|        |
|--------|
|        |  |  |  |  |
|   |   | CALADRIUS BIOSCIENCES, INC. |
|   |   |   |   |   |
|   |   | By: | /s/ David J. Mazzo |   |
|   |   | Name: | David J. Mazzo, PhD |
|   |   | Title: | Chief Executive Officer |
|   |   |   |   |   |
|   |   | By: | /s/ Joseph Talamo |   |
|   |   | Name: | Joseph Talamo |   |
|   |   | Title: | Chief Financial Officer |   |

----

|           |
|-----------|
|           |  |
| 3.1       | Amended and Restated Certificate of Incorporation of Caladrius Biosciences, Inc., filed with the Secretary of State of the State of Delaware on October 3, 3013 (filed as Exhibit 3.1 to the Company's Current Report on Form 8-K dated October 3, 2013 and incorporated herein by reference), and amended by Certificate of Amendment to Certificate of Incorporation of Caladrius Biosciences, Inc., dated May 29, 2015 and made effective June 8, 2915 (filed as Exhibit 3.2 to the Company's Quarterly Report Form 10-Q dated August 6, 2015 and incorporated herein by reference). |
| 3.2       | Amended and Restated By-Laws dated January 5, 2015 (filed as Exhibit 3.1 to the Company's Current Report on Form 8-K on January 5, 2015, and incorporated herein by reference). |
| 4.1**     | Form of Warrant |
| 10.1**    | Unit Purchase Agreement, dated March 11, 2016, by and among Caladrius Biosciences, Inc., PCT, LLC, a Caladrius Company and Hitachi Chemical Co. America, LTD. |
| 10.2**    | Amended and Restated Operating Agreement of PCT, LLC, a Caladrius Company, dated March 11, 2016, by and among PCT, LLC, a Caladrius Company, Caladrius Biosciences, Inc. and Hitachi Chemical Co. America, LTD. |
| 10.3*+    | Technology License Agreement, dated March 22, 2016, by and between PCT, LLC, a Caladrius Company and Hitachi Chemical Co. LTD. |
| 10.4**    | Amended and Restated Employment Agreement, dated March 11, 2016, by and between Caladrius Biosciences, Inc. and Robert A. Preti, PhD. |
| 10.5**    | Employment Agreement, dated March 11, 2016, by and between PCT, LLC, a Caladrius Company and Robert A. Preti, PhD. |
| 10.6**    | Consent and Third Amendment to Loan and Security Agreement, dated March 11, 2016, by and between Caladrius Biosciences, Inc., and Oxford Finance LLC. |
| 10.7**    | Securities Purchase Agreement, dated March 10, 2016, by and among Caladrius Biosciences, Inc., TJP Opportunities Fund L.L.C., GPP Opportunities Fund L.L.C. and IEA Private Investments LTD. |
| 10.8**    | Registration Rights Agreement, dated March 10, 2016, by and among Caladrius Biosciences, Inc., TJP Opportunities Fund L.L.C., GPP Opportunities Fund L.L.C. and IEA Private Investments LTD. |
| 31.1*     | Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
| 31.2*     | Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
| 32.1**    | Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
| 32.2**    | Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
| 101.INS** | XBRL Instance Document |
| 101.SCH** | XBRL Taxonomy Extension Schema |
| 101.CAL** | XBRL Taxonomy Extension Calculation Linkbase |
| 101.DEF** | XBRL Taxonomy Extension Definition Linkbase |
| 101.LAB** | XBRL Taxonomy Extension Label Linkbase |
| 101.PRE** | XBRL Taxonomy Extension Presentation Linkbase |

|    |
|----|
|    |  |
| *  | Filed herewith |
| ** | Filed or furnished with the Original 10-Q |
| +  | Confidential treatment requested as to certain portions, which portions have been provided separately to the Securities and Exchange Commission |